Revenue qualityWarning
매출채권 증가율이 매출 증가율의 1.5배 초과 (3기 연속) — 매출 인식 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Cryo Cell International
CCEL-US · NYSE Amex$3.42+1.79%
2026-07-31 closeCryo Cell International — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p
Beat the market on 57.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 759 건강관리 peers · not investment advice
Valuation in its own history
PER 68.54 · PBR — — own history (2000-01~) percentiles 56/100 · —/100
PER56/100
PBR—/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 2 consecutive years · Raised 1 consecutive years · Yield 11.70% (based on 2025 payment of $0.40)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -2.39
Distress
Grey
Safe
- Altman Z''
- -2.39
- Beneish M-Score
- -2.71
- Sloan accrual
- -8.67%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioPass
- No new sharesNot passed
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Balance sheetDanger
자본잠식 — 자본총계가 마이너스입니다. 부실 위험을 나타내는 사실 지표입니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 168% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-08-03건강관리
This stock is in 건강관리: revenue rank 362 of 553, share 0%.
362 / 5530%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Cryo Cell International0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 22
Value lens
- P90/P10
- 23.8
- Median P/B
- 3.07
- Level
- 넓음
- n
- 467
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 10.9%
- Interest coverage
- 1.9x
- Return on equity (ROE)
- —
Operating margin −5pp
Interest coverage riskInterest coverageBase 1.9x adverse case 1x
Return on equity (ROE)Base — adverse case —
Revenue −15%
TolerableInterest coverageBase 1.9x adverse case 1.6x
Return on equity (ROE)Base — adverse case —
Interest rate +2pp
Interest coverage riskInterest coverageBase 1.9x adverse case 1x
Return on equity (ROE)Base — adverse case —
Interest coverage limit
Current margin 5.1ppInterest coverage limit at an operating margin of 5.8%
Interest expense coverage threshold
Financials at a glance
Cryo Cell International's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
Same theme
AABBCord Blood Association
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
New MA alignment×3
26-06-23-9.2%26-06-10-5.8%26-06-08-6.4%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy